Taylor Melton-Farley
Primary Care · Bel Air, MDNPI 1790350239
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,389 and has fallen 97.8% since, to $31 in 2025. Among primary care clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$374
- Boehringer Ingelheim$347
- AbbVie$272
- AstraZeneca$253
- Lilly USA, LLC$227
- GSK$183
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,680100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $374 |
| Boehringer Ingelheim | 10 | $347 |
| AbbVie | 15 | $272 |
| AstraZeneca | 8 | $253 |
| Lilly USA, LLC | 13 | $227 |
| GSK | 8 | $183 |
| Abbott | 3 | $164 |
| Johnson & Johnson | 3 | $118 |
| Esperion Therapeutics, Inc. | 5 | $83 |
| Novartis | 4 | $80 |
| Amgen | 4 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| Pfizer | 3 | $49 |
| Merck | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Bayer | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Almatica Pharma LLC | 1 | $22 |
| Antares Pharma, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Exact Sciences | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre Pro$131
- BREZTRI$128
- JARDIANCE$125
- Ozempic$100
How this compares
$2,692 in reported general payments places this provider in the 90th percentile of 191 primary care providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 32 | $57,372 |
| TrulicityDulaglutide | 16 | $31,771 |
| JardianceEmpagliflozin | 19 | $30,474 |
| JanuviaSitagliptin Phosphate | 19 | $11,017 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,273 |
| Ezetimibe | 66 | $3,163 |
| Rosuvastatin Calcium | 56 | $1,664 |
| Pioglitazone Hcl | 22 | $692 |
| Atorvastatin Calcium | 37 | $626 |
| Fluticasone Propionate | 26 | $577 |
| Famotidine | 27 | $461 |
| Pantoprazole Sodium | 30 | $385 |
| Levothyroxine Sodium | 34 | $347 |
| Pravastatin Sodium | 14 | $335 |
| Metoprolol Succinate | 22 | $321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $374 | $57,37232 claims |
| Lilly USA, LLCTrulicity | $227 | $31,77116 claims |
| Boehringer IngelheimJardiance | $347 | $30,47419 claims |
| MerckJanuvia | $48 | $11,01719 claims |
| GSKTrelegy Ellipta | $183 | $10,27311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 191 primary care providers in Maryland.
Other primary care in Bel Air
- Laura Ferguson-WeigmanBel Air$5K
- Mary WeberBel Air$3K
- Samantha MarseeBel Air$3K
- Vicki HyattBel Air$3K
- Tara McDonaldBel Air$2K
- Donna BakerBel Air$2K
- Kimberly MorelandBel Air$2K
- Agatha HughesBel Air$2K
- Tyler CoakleyBel Air$798
- Ashley SalamoneBaltimore$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.